PMID- 18946352
OWN - NLM
STAT- MEDLINE
DCOM- 20081113
LR  - 20181113
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 86
IP  - 8
DP  - 2008 Oct 27
TI  - Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ 
      myeloid-derived suppressor cells that promote long-term survival of allografts.
PG  - 1125-34
LID - 10.1097/TP.0b013e318186fccd [doi]
AB  - BACKGROUND: The expression of human leukocyte antigen (HLA)-G during allogeneic 
      recognition is associated with better graft acceptance. The inhibitory receptor 
      immunoglobulin-like transcript (ILT)-2 is expressed on activated T cells and 
      serves to shut down T-cell activation, culminating in T-cell death, or induction 
      of anergy. One of the potential mechanisms in the immunosuppressive 
      accomplishment of HLA-G-ILT2 interactions involves the expansion of 
      myeloid-derived suppressor cells (MDSCs). The potential of MDSCs in 
      transplantation has not yet been exploited. METHODS: (1) Detailed phenotypic 
      characteristics, immunosuppressive potential of MDSCs expanded by means of 
      inhibitory receptor ILT2 and its ligands, and allogeneic transplant-activated 
      MDSCs were obtained in mice. (2) Oligo- and real-time pathway-specific polymerase 
      chain reaction arrays were performed to characterize ILT2-specific MDSCs. (3) 
      Skin allograft survival after adoptive transfer of MDSCs was studied. RESULTS: 
      Engagement of ILT2 receptors, especially by HLA-G, expanded the population of 
      MDSCs with enhanced suppressive activity. Adoptive transfer of MDSCs generated by 
      ILT2 receptor and its ligands prolonged graft survival in recipients of 
      allogeneic skin transplant. We have proposed pathways for enhancement of 
      immunosuppressive activities and expansion of MDSCs by ILT2 and HLA-G. 
      CONCLUSIONS: Our results suggest that induction of MDSCs using ILT2 inhibitory 
      receptor/HLA-G ligand may be an attractive strategy for preventing rejection of 
      immunogenic organs or tissues in clinical transplantation.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Medicine, Center for Molecular Chaperone/Radiobiology and Cancer 
      Virology, Medical College of Georgia, Augusta, GA, USA.
FAU - Liang, Siyuan
AU  - Liang S
FAU - Wu, Juan
AU  - Wu J
FAU - Horuzsko, Anatolij
AU  - Horuzsko A
LA  - eng
GR  - R01 AI055923/AI/NIAID NIH HHS/United States
GR  - R01 AI055923-04/AI/NIAID NIH HHS/United States
GR  - R01 AI055923-05/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Antigens, CD)
RN  - 0 (CD11b Antigen)
RN  - 0 (Gr-1 protein, mouse)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (LILRB1 protein, human)
RN  - 0 (Leukocyte Immunoglobulin-like Receptor B1)
RN  - 0 (Ligands)
RN  - 0 (Receptors, Chemokine)
RN  - 0 (Receptors, Immunologic)
SB  - IM
MH  - Adoptive Transfer
MH  - Animals
MH  - Antigens, CD/genetics/*metabolism
MH  - CD11b Antigen/*metabolism
MH  - Cell Movement/immunology
MH  - *Cell Proliferation
MH  - Cells, Cultured
MH  - Graft Rejection/genetics/immunology/*prevention & control
MH  - Graft Survival/genetics/*immunology
MH  - HLA Antigens/metabolism
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Humans
MH  - *Immune Tolerance/genetics
MH  - Leukocyte Immunoglobulin-like Receptor B1
MH  - Ligands
MH  - Lymphocyte Activation
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Myeloid Cells/*immunology/transplantation
MH  - Phenotype
MH  - Receptors, Chemokine/*metabolism
MH  - Receptors, Immunologic/genetics/*metabolism
MH  - *Skin Transplantation
MH  - T-Lymphocytes/immunology
MH  - Time Factors
MH  - Transcription, Genetic
MH  - Transplantation, Homologous
PMC - PMC2668611
MID - NIHMS84838
COIS- Conflict of interest disclosure: The authors declare no potential conflict of 
      interest.
EDAT- 2008/10/24 09:00
MHDA- 2008/11/14 09:00
PMCR- 2009/10/27
CRDT- 2008/10/24 09:00
PHST- 2008/10/24 09:00 [pubmed]
PHST- 2008/11/14 09:00 [medline]
PHST- 2008/10/24 09:00 [entrez]
PHST- 2009/10/27 00:00 [pmc-release]
AID - 00007890-200810270-00017 [pii]
AID - 10.1097/TP.0b013e318186fccd [doi]
PST - ppublish
SO  - Transplantation. 2008 Oct 27;86(8):1125-34. doi: 10.1097/TP.0b013e318186fccd.